

Rikke Fredslund Andersen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5217189/publications.pdf>

Version: 2024-02-01

17
papers

312
citations

1162889

8
h-index

887953

17
g-index

18
all docs

18
docs citations

18
times ranked

466
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Reporting on circulating tumor DNA monitoring in metastatic cancer – From clinical validity to clinical utility. <i>Cancer</i> , 2022, 128, 2052-2057. | 2.0 | 7 |
| 2 | Prognostic Impact of Circulating Methylated Homeobox A9 DNA in Patients Undergoing Treatment for Recurrent Ovarian Cancer. <i>Cancers</i> , 2022, 14, 1766. | 1.7 | 6 |
| 3 | Natural killer cell activity as a biomarker for the diagnosis of lung cancer in high-risk patients. <i>Journal of International Medical Research</i> , 2022, 50, 030006052211089. | 0.4 | 3 |
| 4 | The prognostic impact of circulating homeobox A9 methylated DNA in advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 855-865. | 1.3 | 7 |
| 5 | Early ctDNA response to chemotherapy. A potential surrogate marker for overall survival. <i>European Journal of Cancer</i> , 2021, 149, 128-133. | 1.3 | 20 |
| 6 | Validating Methylated HOXA9 in Bronchial Lavage as a Diagnostic Tool in Patients Suspected of Lung Cancer. <i>Cancers</i> , 2021, 13, 4223. | 1.7 | 3 |
| 7 | Performance of the EarlyCDT [®] Lung test in detection of lung cancer and pulmonary metastases in a high-risk cohort. <i>Lung Cancer</i> , 2021, 158, 85-90. | 0.9 | 13 |
| 8 | Analysis of HOXA9 methylated ctDNA in ovarian cancer using sense-antisense measurement. <i>Clinica Chimica Acta</i> , 2021, 522, 152-157. | 0.5 | 7 |
| 9 | Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer. <i>European Journal of Cancer</i> , 2020, 125, 121-129. | 1.3 | 32 |
| 10 | Comparison of Mutated KRAS and Methylated HOXA9 Tumor-Specific DNA in Advanced Lung Adenocarcinoma. <i>Cancers</i> , 2020, 12, 3728. | 1.7 | 6 |
| 11 | Decreased concentrations of intracellular signaling proteins in colon cancer patients with BRAF mutations. <i>Scientific Reports</i> , 2020, 10, 20113. | 1.6 | 5 |
| 12 | NPY Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer. <i>Cancers</i> , 2019, 11, 1649. | 1.7 | 17 |
| 13 | Correlation Between Tumor-Specific Mutated and Methylated DNA in Colorectal Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-8. | 1.5 | 7 |
| 14 | Delta tocotrienol in recurrent ovarian cancer. A phase II trial. <i>Pharmacological Research</i> , 2019, 141, 392-396. | 3.1 | 47 |
| 15 | The prognostic value of simultaneous tumor and serum <sc>RAS</sc>/<sc>RAF</sc> mutations in localized colon cancer. <i>Cancer Medicine</i> , 2017, 6, 928-936. | 1.3 | 15 |
| 16 | International Interlaboratory Digital PCR Study Demonstrating High Reproducibility for the Measurement of a Rare Sequence Variant. <i>Analytical Chemistry</i> , 2017, 89, 1724-1733. | 3.2 | 54 |
| 17 | Controls to validate plasma samples for cell free DNA quantification. <i>Clinica Chimica Acta</i> , 2015, 446, 141-146. | 0.5 | 63 |